Obenow 10mg Tablet contains obeticholic acid, a potent farnesoid X receptor (FXR) agonist indicated primarily for the treatment of primary biliary cholangitis (PBC) in adult patients with an inadequate response to ursodeoxycholic acid or as monotherapy in those intolerant to ursodeoxycholic acid. Obeticholic acid exerts its therapeutic effect by modulating bile acid synthesis and transport, thereby reducing hepatic inflammation and fibrosis associated with cholestatic liver diseases. The recommended dosage is 10mg once daily, with dose adjustments based on patient response and tolerability. Obenow is contraindicated in patients with complete biliary obstruction and should be used cautiously in those with advanced hepatic impairment. Common adverse effects include pruritus, fatigue, abdominal discomfort, and headache, which are generally mild to moderate in severity. Liver function tests should be monitored regularly to assess treatment efficacy and detect potential hepatotoxicity. Obenow should be prescribed under specialist supervision, with consideration of individual patient risk factors and concomitant medications to avoid drug interactions. This medication offers a valuable therapeutic option for managing PBC, improving biochemical markers, and potentially delaying disease progression. Patients are advised to adhere strictly to prescribed dosing and report any adverse symptoms promptly to their healthcare provider.